Literature DB >> 18334978

Mechanisms of disease: aquaporin-4 antibodies in neuromyelitis optica.

Sven Jarius1, Friedemann Paul, Diego Franciotta, Patrick Waters, Frauke Zipp, Reinhard Hohlfeld, Angela Vincent, Brigitte Wildemann.   

Abstract

Neuromyelitis optica (NMO) is a rare CNS inflammatory disorder that predominantly affects the optic nerves and spinal cord. Recent serological findings strongly suggest that NMO is a distinct disease rather than a subtype of multiple sclerosis. In NMO, serum antibodies, collectively known as NMO-IgG, characteristically bind to cerebral microvessels, pia mater and Virchow-Robin spaces. The main target antigen for this immunoreactivity has been identified as aquaporin-4 (AQP4). The antibodies are highly specific for NMO, and they are also found in patients with longitudinally extensive transverse myelitis without optic neuritis, which is thought to be a precursor to NMO in some cases. An antibody-mediated pathogenesis for NMO is supported by several observations, including the characteristics of the AQP4 antibodies, the distinct NMO pathology--which includes IgG and complement deposition and loss of AQP4 from spinal cord lesions--and emerging evidence of the beneficial effects of B-cell depletion and plasma exchange. Many aspects of the pathogenesis, however, remain unclear.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18334978     DOI: 10.1038/ncpneuro0764

Source DB:  PubMed          Journal:  Nat Clin Pract Neurol        ISSN: 1745-834X


  115 in total

1.  Neutrophil protease inhibition reduces neuromyelitis optica-immunoglobulin G-induced damage in mouse brain.

Authors:  Samira Saadoun; Patrick Waters; Claire MacDonald; B Anthony Bell; Angela Vincent; A S Verkman; Marios C Papadopoulos
Journal:  Ann Neurol       Date:  2012-02-28       Impact factor: 10.422

2.  Antibodies to aquaporin-4 in non-small cell lung cancer: a study on 50 patients.

Authors:  S Jarius; A Warth; K P Wandinger; P A Schnabel; H Hoffmann; B Wildemann; T Muley
Journal:  Neurol Sci       Date:  2010-05-27       Impact factor: 3.307

Review 3.  Neurology--the next 10 years.

Authors:  Ralf Baron; Donna M Ferriero; Giovanni B Frisoni; Chetan Bettegowda; Ziya L Gokaslan; John A Kessler; Annamaria Vezzani; Stephen G Waxman; Sven Jarius; Brigitte Wildemann; Michael Weller
Journal:  Nat Rev Neurol       Date:  2015-10-27       Impact factor: 42.937

4.  Neuromyelitis optica presenting as intractable vomiting and hyperCKaemia.

Authors:  Tarig Mohammed Abkur; Eílis Foran; Hugh Kearney; Grace Harkin; Valerie Byrnes; John Lynch
Journal:  J Neurol       Date:  2015-11-21       Impact factor: 4.849

5.  Anti-aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica.

Authors:  Lukmanee Tradtrantip; Hua Zhang; Samira Saadoun; Puay-Wah Phuan; Chiwah Lam; Marios C Papadopoulos; Jeffrey L Bennett; A S Verkman
Journal:  Ann Neurol       Date:  2012-01-23       Impact factor: 10.422

6.  Small-molecule inhibitors of NMO-IgG binding to aquaporin-4 reduce astrocyte cytotoxicity in neuromyelitis optica.

Authors:  Lukmanee Tradtrantip; Hua Zhang; Marc O Anderson; Samira Saadoun; Puay-Wah Phuan; Marios C Papadopoulos; Jeffrey L Bennett; A S Verkman
Journal:  FASEB J       Date:  2012-02-08       Impact factor: 5.191

Review 7.  Losing your nerves? Maybe it's the antibodies.

Authors:  Betty Diamond; Patricio T Huerta; Paola Mina-Osorio; Czeslawa Kowal; Bruce T Volpe
Journal:  Nat Rev Immunol       Date:  2009-06       Impact factor: 53.106

Review 8.  Aquaporins: translating bench research to human disease.

Authors:  A S Verkman
Journal:  J Exp Biol       Date:  2009-06       Impact factor: 3.312

9.  The history of neuromyelitis optica.

Authors:  Sven Jarius; Brigitte Wildemann
Journal:  J Neuroinflammation       Date:  2013-01-15       Impact factor: 8.322

10.  Multifrequency magnetic resonance elastography of the brain reveals tissue degeneration in neuromyelitis optica spectrum disorder.

Authors:  Kaspar-Josche Streitberger; Andreas Fehlner; Florence Pache; Anna Lacheta; Sebastian Papazoglou; Judith Bellmann-Strobl; Klemens Ruprecht; Alexander Brandt; Jürgen Braun; Ingolf Sack; Friedemann Paul; Jens Wuerfel
Journal:  Eur Radiol       Date:  2016-08-29       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.